Combinatorial effects of VEGFR kinase inhibitor axitinib and oncolytic virotherapy in mouse and human glioblastoma stem-like cell models.
CONCLUSIONS: Systemic TKI (axitinib) beneficially combines with G47Δ-mIL12 to enhance anti-tumor efficacy in both immune-deficient and immune-competent orthotopic Saha et al 4 GBM models. Our results support further investigation of TKIs in combination with oHSV for GBM treatment.
PMID: 29599413 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Saha D, Wakimoto H, Peters CW, Antoszczyk SJ, Rabkin SD, Martuza RL Tags: Clin Cancer Res Source Type: research
More News: Brain | Brain Cancers | Brain Tumor | Cancer | Cancer & Oncology | Cold Sores | Glioma | Herpes | Neurology | Virotherapy